Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 8Dermatologic 4Thoracic 2Gastrointestinal 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Cisplatin 631Radiotherapy 339pembrolizumab 329Cetuximab 284Docetaxel 226Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 77toripalimab 75Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 50Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 44130-nm albumin-bound paclitaxel 44tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tovorafenib × Head & Neck × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡